{
"@context": "https://schema.org",
"@type": "Article",
"headline": "CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK",
"url": "https://www.lexblog.com/2016/02/12/cma-fines-glaxosmithkline-and-several-generic-companies-45-million-for-delaying-market-entry-of-generic-paroxetine-in-the-uk-2/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-TPVQJN66",
"url": "https://www.lexblog.com/lib/TPVQJN66/"
},
"datePublished": "2016-02-12T13:23:47-05:00",
"dateModified": "2022-08-25T14:22:24-04:00",
"author": {
"@type": "Person",
"name": "Inside EU Life Sciences"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Covington & Burling LLP"
},
"organizationScope": "at-publication",
"isPartOf": "Inside EU Life Sciences",
"about": "Antitrust, Competition and Trade",
"sourceUrl": "https://www.insideeulifesciences.com/?p=6481",
"sourceStability": "may-move"
}